Sažetak
Objective: To explore the assessment value of pathological condition of serum adiponectin (APN) and Amylin in primary osteoporosis (POP) and their correlation with bone metabolism indexes.
Methods: From January 2019 to June 2021, selection of 79 cases of POP patients was as the research objects. Test of the bone density of the patients was conducted, and clinical grading of POP was via T value (normal, mild, moderate, severe). Analysis of the assessment value of pathological condition of serum APN and Amylin for POP and their association with bone metabolism indexes in patients was performed.
Results: APN and Amylin in patients were declined with POP’s aggravation. Patients with APN of 5.15 μg/mL or less and Amylin of 15.38 pmol/L or less were risk factors influencing the aggravation of pathological condition of POP (P < 0.05); The area under the curve (AUC) of combined detection of APN and Amylin to assess the severity of POP was elevated vs. alone test of Amylin (P < 0.05); 25-hydroxyvitamin D (25-(OH) D) and total type 1 procollagen amino-terminal propeptide (t-PINP) in patients were descended with the aggravation of pathological condition of osteoporosis (P < 0.05), while no distinct differences were presented in the three groups of type I collagen hydroxyl terminal peptide β degradation product (β-CTX) and N-terminal osteocalcin (N-MID) (P > 0.05); APN, Amylin, 25-(OH)D, β-CTX and t-PINP were negatively linked with POP clinical grade (P < 0.05); APN and Amylin were associated with 25-(OH) D, β-CTX, t-PINP (P < 0.05), and APN and Amylin were not linked with N-MID (P > 0.05).
Conclusions: Serum APN and Amylin are provided with evaluation value for the severity of POP, and are associated with the bone metabolism in patients.
Ključne reči
Array
Array
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.